To see all protocols that comply with the WHO Essential Medicine List 
 Warning: QT prolongation, torsades de pointes and sudden death:

Vandetanib can prolong the QT interval and may cause fatal or life-threatening ventricular arrhythmias (including torsades de pointes) or sudden death.  Vandetanib should not be commenced in patients with QTc >480 ms, congenital long QT syndrome or a history of arrhythmias (unless all contributing risk factors have been corrected). ECG and electrolytes should be monitored at baseline and regularly throughout treatment. Drugs known to prolong the QT interval should be avoided. Caution is advised if concomitant CYP3A4 inhibitors are used, as vandetanib is metabolised by CYP3A4. Vandetanib has a long half life - the risk of QT prolongation and arrhythmia may remain for a period of weeks after cessation of therapy.

Check for clinical trials in this patient group. Link to Australian Clinical Trials website

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

08 Aug 2020